BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/20/2025 7:38:49 AM | Browse: 132 | Download: 657
 |
Received |
|
2024-09-23 02:50 |
|
Peer-Review Started |
|
2024-09-23 02:50 |
|
First Decision by Editorial Office Director |
|
2024-11-22 05:03 |
|
Return for Revision |
|
2024-11-22 05:03 |
|
Revised |
|
2024-12-03 14:15 |
|
Publication Fee Transferred |
|
2024-12-05 10:33 |
|
Second Decision by Editor |
|
2024-12-30 02:36 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-12-30 06:23 |
|
Articles in Press |
|
2024-12-30 06:23 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-01-10 02:50 |
|
Publish the Manuscript Online |
|
2025-01-20 07:38 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
CRAFITY score and nomogram predict the clinical efficacy of lenvatinib combined with immune checkpoint inhibitors in hepatocellular carcinoma
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Xue Yin, Na Deng, Xiao-Yan Ding, Jing-Long Chen and Wei Sun |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| the Capital’s Funds for Health Improvement and Research |
SF202222175 |
|
| Corresponding Author |
Wei Sun, MD, Department of Cancer Center, Beijing Ditan Hospital, Capital Medical University, No. 8 Jingshun East Street, Chaoyang District, Beijing 100015, China. sunwei2134@163.com |
| Key Words |
Hepatocellular carcinoma; Lenvatinib; Immune checkpoint inhibitors; C-reactive protein; Alpha-fetoprotein |
| Core Tip |
The CRAFITY score, integrating baseline alpha-fetoprotein and C-reactive protein levels, has been limitedly investigated in patients receiving lenvatinib and programmed cell death protein 1 (PD-1) inhibitors. This study found significant differences in progression-free survival and overall survival across CRAFITY score strata in patients treated with lenvatinib and PD-1 inhibitors. Lower CRAFITY scores were associated with better objective response rates and disease control rates. These findings suggest that the CRAFITY score is a promising predictive tool for treatment response and survival in patients with unresectable hepatocellular carcinoma receiving lenvatinib and PD-1 inhibitors. |
| Publish Date |
2025-01-20 07:38 |
| Citation |
Yin X, Deng N, Ding XY, Chen JL, Sun W. CRAFITY score and nomogram predict the clinical efficacy of lenvatinib combined with immune checkpoint inhibitors in hepatocellular carcinoma. World J Gastroenterol 2025; 31(7): 101672 |
| URL |
https://www.wjgnet.com/1007-9327/full/v31/i7/101672.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v31.i7.101672 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
